Affordable Access

DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components.

Authors
  • Hahn, Ulrike K
  • Boehm, Reinhard
  • Beyer, Wolfgang
Type
Published Article
Journal
Vaccine
Publisher
Elsevier
Publication Date
May 22, 2006
Volume
24
Issue
21
Pages
4569–4571
Identifiers
PMID: 16157424
Source
Medline
License
Unknown

Abstract

The predominant antigen in human anthrax vaccines is the protective antigen (PA) of Bacillus anthracis. To address the question whether immune responses against B. anthracis spores can improve the protectivity of a PA-based DNA vaccine against anthrax, we designed a eucaryotic expression plasmid encoding the exosporium antigen BclA, which is a collagen-like surface protein. This plasmid, pSecTag BclA, carries a secretion signal for the recombinant antigen. Using NMRI mice we compared the effects of immunisation with a combination of PA- and BclA-encoding plasmid DNA, to immunisations with either PA- or BclA-encoding pDNA. After three immunisations the mice were infected with 25 x LD(50) of B. anthracis Ames spores. The plasmid pSecTag BclA, induced high BclA-specific antibody responses. Vaccination with a combination of PA- and BclA-encoding pDNA led to significantly better survival than immunisation with only PA- or only BclA-encoding plasmids.

Report this publication

Statistics

Seen <100 times